Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short term Debt: 2014-2020

Historic Short term Debt for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Dec 2020 value amounting to $523,000.

  • Lineage Cell Therapeutics' Short term Debt was N/A to $523,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $523,000, marking a year-over-year change of. This contributed to the annual value of $523,000 for FY2020, which is N/A change from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Short term Debt stood at $523,000 for FY2020, which was up 1,911.54% from $26,000 recorded in FY2015.
  • In the past 5 years, Lineage Cell Therapeutics' Short term Debt registered a high of $523,000 during FY2020, and its lowest value of $523,000 during FY2020.
  • In the last 1 years, Lineage Cell Therapeutics' Short term Debt had a median value of $523,000 in 2020 and averaged $523,000.